Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
3186studies shown
Showing 2,576-2,600 of 3,186
CompletedNCT00845026

A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients

This study exists to understand how brain scans or other body measurements holds up over time after the earliest research stage. Researchers are trying to understand how people respond to brain scans or other body measurements in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
Germany, Mexico, Russian Federation, United States
Sponsor
Denovo Biopharma LLC
Condition
Schizophrenia
CompletedNCT02411526

Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia

This study exists to better understand the safety of a digital app or remote support tool and how manageable it feels in practice. Researchers are trying to understand whether a digital app or remote support tool can give earlier or clearer feedback during care.

SchizophreniaOtherFrom 18 Years to 60 Years
Countries
United States
Sponsor
Zogenix, Inc.
Condition
Schizophrenia
TerminatedNCT01307800

A Study of LY2140023 in Patients With Schizophrenia

This study exists to compare options and see whether the medication LY2140023 offers something meaningfully different. Researchers are trying to understand whether the medication LY2140023 can give earlier or clearer feedback during care.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
Mexico, United States, Russian Federation, Ukraine
Sponsor
Denovo Biopharma LLC
Condition
Schizophrenia
WithdrawnNCT05338424

Exercise Target Brain Oscillations in Psychosis

This study exists to explore whether this type of care could improve care and understanding. Researchers are trying to understand whether this type of care can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 64 Years
Countries
United States
Sponsor
University of Minnesota
Condition
Schizophrenia
CompletedNCT01555697

Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia

This study exists to see whether a therapy or guided support program is workable and worth testing more broadly. Researchers are trying to understand whether a therapy or guided support program can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
United States
Sponsor
University of California, San Diego
Condition
Schizophrenia
CompletedNCT04173572

Targeting Physical Health in Schizophrenia: Physical Activity Can Enhance Life Randomized Control Trial

This study exists to see whether a digital app or remote support tool can make care clearer and more responsive. Researchers are trying to understand whether a digital app or remote support tool can make support easier to access outside standard clinic visits.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
University of North Carolina, Chapel Hill
Condition
Schizophrenia
TerminatedNCT04103775

Mechanisms of Cognitive Change

This study exists to compare options and see whether a therapy or guided support program offers something meaningfully different. Researchers are trying to understand whether a therapy or guided support program can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 15 Years to 100 Years
Countries
United States
Sponsor
Colorado State University
Condition
Schizophrenia
CompletedNCT01354353

A Study of Safety and Tolerability in Subjects With Schizophrenia

This study exists to better understand the safety of the medication Safety and how manageable it feels in practice. Researchers are trying to understand how people respond to the medication Safety in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Denovo Biopharma LLC
Condition
Schizophrenia
CompletedNCT01452919

A Physical Dependence Study in Schizophrenia

This study exists to explore whether a medication treatment could improve care and understanding. Researchers are trying to understand whether a medication treatment can give earlier or clearer feedback during care.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
Greece, United States
Sponsor
Denovo Biopharma LLC
Condition
Schizophrenia
CompletedNCT03873337

Persistence Targeted Smoking Cessation in Serious Mental Illness (SMI)

This study exists to see whether smoking support or smoking-related treatment is workable and worth testing more broadly. Researchers are trying to understand whether smoking support or smoking-related treatment can make support easier to access outside standard clinic visits.

SchizophreniaOtherFrom 18 Years to 70 Years
Countries
United States
Sponsor
Rutgers, The State University of New Jersey
Condition
Schizophrenia
TerminatedNCT01328093

A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients

This study exists to explore whether the medication LY2140023 could improve care and understanding. Researchers are trying to understand how people respond to the medication LY2140023 in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
Austria, Belgium, France, Germany, Poland, United States, Romania, Spain, Sweden
Sponsor
Denovo Biopharma LLC
Condition
Schizophrenia
CompletedNCT01052103

A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms

This study exists to explore whether the medication LY2140023 could improve care and understanding. Researchers are trying to understand whether the medication LY2140023 can give earlier or clearer feedback during care.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
Israel, Italy, Spain, United States
Sponsor
Denovo Biopharma LLC
Condition
Schizophrenia
CompletedNCT02504151

Cannabidiol Treatment in Patients With Early Psychosis

This study exists to see whether a medication treatment can make care clearer and more responsive. Researchers are trying to understand whether a medication treatment can give earlier or clearer feedback during care.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Yale University
Condition
Schizophrenia
CompletedNCT02686697

Carnosine and Cognitive Training in Schizophrenia

This study exists to compare options and see whether a digital app or remote support tool offers something meaningfully different. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 60 Years
Countries
United States
Sponsor
Abraham Reichenberg
Condition
Schizophrenia
CompletedNCT03576976

Improving Accessibility and Personalization of CR for Schizophrenia

This study exists to see whether a digital app or remote support tool is workable and worth testing more broadly. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
New York State Psychiatric Institute
Condition
Schizophrenia
TerminatedNCT02739347

Non-Invasive Direct Current Stimulation for Cognition in Schizophrenia

This study exists to compare options and see whether a digital app or remote support tool offers something meaningfully different. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 50 Years
Countries
United States
Sponsor
Baylor College of Medicine
Condition
Schizophrenia
CompletedNCT03711500

D-serine Augmentation of Neuroplasticity

This study exists to understand what helps a digital app or remote support tool work in everyday practice, not just under ideal conditions. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 50 Years
Countries
United States
Sponsor
New York State Psychiatric Institute
Condition
Schizophrenia
CompletedNCT01100775

Effects of Galantamine on Cognition

This study exists to explore whether a medication treatment could improve care and understanding. Researchers are trying to understand whether a medication treatment can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 64 Years
Countries
United States
Sponsor
University of Maryland, Baltimore
Condition
Schizophrenia
CompletedNCT02782442

Cognitive Training Delivered Remotely to Individuals With Psychosis (ROAM)

This study exists to understand how a guided support group holds up over time after the earliest research stage. Researchers are trying to understand whether a guided support group can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 60 Years
Countries
United States
Sponsor
University of Minnesota
Condition
Schizophrenia
WithdrawnNCT05140135

Effectiveness and Mechanisms of Recovery Oriented Cognitive Therapy

This study exists to see whether a therapy or guided support program can play a useful role in care. Researchers are trying to understand whether a therapy or guided support program can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
University of Pennsylvania
Condition
Schizophrenia
TerminatedNCT03507127

Targeted Pharmacological and Behavioral Treatments for Smoking in Schizophrenia Study 1

This study exists to explore whether smoking support or smoking-related treatment could improve care and understanding. Researchers are trying to understand whether smoking support or smoking-related treatment can better prevent setbacks and support longer-term stability.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Brown University
Condition
Schizophrenia
TerminatedNCT03838484

Effects of Transdermal Nicotine on Response Inhibition to Emotional Cues in Schizophrenia

This study exists to compare options and see whether smoking support or smoking-related treatment offers something meaningfully different. Researchers are trying to understand whether smoking support or smoking-related treatment can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Vanderbilt University Medical Center
Condition
Schizophrenia